Clinical Trials Browser

Phase 1 × Has results × Docetaxel × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Squamous-Cell Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumors

Advanced Breast Cancer

Advanced Solid Neoplasm

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

Advanced Solid Neoplasm

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Breast Cancer Metastatic

Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung, Recurrence

Neoplasm Metastasis

Advanced Solid Tumors

Breast Neoplasms

Lymphoma, Neoplasms

Pancreatic Neoplasms

Solid Cancers

Breast Neoplasms

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

FORTITUDE-201

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

EDALINE

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

MK-2206-003

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

PRIMAL

A Safety Study in Participants With Advanced Solid Tumors

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer